Adrenal gland – AR negative adrenocortical adenoma.
Adrenal gland - AR negative adrenocortical adenoma. Breast – Invasive breast cancer of no special type (NST) with moderate to strong AR immunostaining of tumor cells.
Breast - Invasive breast cancer of no special type (NST) with moderate to strong AR immunostaining of tumor cells. Breast – Invasive lobular breast cancer with strong AR immunostaining of tumor cells.
Breast - Invasive lobular breast cancer with strong AR immunostaining of tumor cells. Colon – AR negative colorectal adenocarcinoma.
Colon - AR negative colorectal adenocarcinoma. Esophagus – AR negative adenocarcinoma.
Esophagus - AR negative adenocarcinoma. Esophagus – AR negative squamous cell carcinoma.
Esophagus - AR negative squamous cell carcinoma. Kidney – AR negative clear cell renal cell carcinoma.
Kidney - AR negative clear cell renal cell carcinoma. Kidney – AR negative oncocytoma.
Kidney - AR negative oncocytoma. Kidney – Papillary renal cell carcinoma with moderate to strong AR immunostaining of tumor cells.
Kidney - Papillary renal cell carcinoma with moderate to strong AR immunostaining of tumor cells. Liver – AR negative cholangiocellular carcinoma.
Liver - AR negative cholangiocellular carcinoma. Liver – Hepatocellular carcinoma with moderate to strong AR immunostaining of tumor cells.
Liver - Hepatocellular carcinoma with moderate to strong AR immunostaining of tumor cells. Lung – AR negative adenocarcinoma.
Lung - AR negative adenocarcinoma. Ovary – AR negative clear cell carcinoma.
Ovary - AR negative clear cell carcinoma. Ovary – Serous high-grade carcinoma with moderate AR immunostaining of tumor cells.
Ovary - Serous high-grade carcinoma with moderate AR immunostaining of tumor cells. Pancreas – AR negative ductal adenocarcinoma.
Pancreas - AR negative ductal adenocarcinoma. Pancreas – AR negative neuroendocrine tumor.
Pancreas - AR negative neuroendocrine tumor. Pharynx – AR negative squamous cell carcinoma.
Pharynx - AR negative squamous cell carcinoma. Prostate – Adenocarcinoma (Gleason 4+4=8) showing strong AR immunostaining of tumor cells. Of note: AR staining is weaker in one residual normal prostate gland.
Prostate - Adenocarcinoma (Gleason 4+4=8) showing strong AR immunostaining of tumor cells. Of note: AR staining is weaker in one residual normal prostate gland. Prostate – Adenocarcinoma (Gleason 4+4=8) with strong AR immunostaining.
Prostate - Adenocarcinoma (Gleason 4+4=8) with strong AR immunostaining. Prostate – Adenocarcinoma (Gleason 5+5=10) with strong nuclear and cytoplasmic AR immunostaining of tumor cells.
Prostate - Adenocarcinoma (Gleason 5+5=10) with strong nuclear and cytoplasmic AR immunostaining of tumor cells. Prostate – Recurrent adenocarcinoma of the prostate (Gleason 5+4=9) with subtotal loss of AR expression after castration therapy.
Prostate - Recurrent adenocarcinoma of the prostate (Gleason 5+4=9) with subtotal loss of AR expression after castration therapy. Prostate – Small cell carcinoma with focal weak to moderate AR immunostaining of tumor cells.
Prostate - Small cell carcinoma with focal weak to moderate AR immunostaining of tumor cells. Soft tissue – AR negative leiomyosarcoma.
Soft tissue - AR negative leiomyosarcoma. Stomach – AR negative gastric adenocarcinoma (diffuse type).
Stomach - AR negative gastric adenocarcinoma (diffuse type). Stomach – AR negative gastric adenocarcinoma.
Stomach - AR negative gastric adenocarcinoma. Stomach – AR negative gastrointestinal stromal tumor (GIST).
Stomach - AR negative gastrointestinal stromal tumor (GIST). Testis – AR negative seminoma.
Testis - AR negative seminoma. Thorax – AR negative epitheloid malignant mesothelioma.
Thorax - AR negative epitheloid malignant mesothelioma. Thyroid – AR negative medullary carcinoma.
Thyroid - AR negative medullary carcinoma. Thyroid – AR negative papillary cancer.
Thyroid - AR negative papillary cancer. Urinary bladder – Muscle-invasive urothelial carcinoma with focal weak AR immunostaining in <10% of tumor cells.
Urinary bladder - Muscle-invasive urothelial carcinoma with focal weak AR immunostaining in <10% of tumor cells. Urinary bladder – Muscle-invasive urothelial carcinoma with moderate to strong AR immunostaining of tumor cells.
Urinary bladder - Muscle-invasive urothelial carcinoma with moderate to strong AR immunostaining of tumor cells. Uterus – Endometroid endometrium carcinoma with AR immunostaining of variable intensity in the majority of tumor cells.
Uterus - Endometroid endometrium carcinoma with AR immunostaining of variable intensity in the majority of tumor cells.